// startup autopsy
Marval Pharma
A pharma hopeful that never made it to the clinic
marketfitSlow Death
Years-long decline before final shutdown · Fatal mistake: Marval Pharma failed to secure a licensing or co-development partnership to extend its runway beyond the initial $6.5M in venture capital.
Key Events Timeline
FOUNDING
Marval Pharma founded to develop novel pharmaceutical compounds targeting unmet medical needs.
PRODUCT LAUNCH
Company advances lead compound into preclinical studies, signaling early research progress to investors.
FUNDING
Marval Pharma closes its final funding round at $6.52M, intended to push toward Phase I clinical trials.
PIVOT
Facing lack of clinical progress, company attempts to reposition pipeline and seek licensing deals with larger pharma partners unsuccessfully.
SHUTDOWN
Marval Pharma winds down operations after exhausting funding and failing to advance any drug candidate to clinical trials.